The arrival of GLP-1 receptor agonists, such as semaglutide, and the more recent dual GLP-1/GIP agonist, tirzepatide, has dramatically changed the options for weight loss medication.
Since both have proven to be powerful tools for losing weight, many are keen to know which one works best.
This article offers a comparative look to help you understand this rapidly advancing area.
Understanding the Mechanisms
Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight loss, belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It works by imitating the effects of the body’s natural GLP-1 hormone, which is vital for controlling both appetite and blood sugar.
Semaglutide works by:
Slowing down gastric emptying, leading to a prolonged feeling of fullness.
Suppressing appetite signals in the brain.
It also boosts the release of insulin and reduces the secretion of glucagon, actions that are particularly important for managing blood sugar levels.
Tirzepatide, known as Mounjaro for type 2 diabetes and Zepbound for weight loss, is a unique medication that acts on two receptors: both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). GIP is another hormone produced in the gut that helps the body release more insulin.
Tirzepatide’s dual action offers a more comprehensive approach to weight management by:
Exhibiting similar effects to semaglutide on gastric emptying and appetite.
It might also amplify these effects by activating the GIP receptor.
Influencing fat storage and metabolism through GIP.
Head-to-Head Efficacy for Weight Loss
Multiple studies have looked at how well tirzepatide and semaglutide work for weight loss. Although we’re still waiting for direct, long-term studies comparing them, the information we have now hints that tirzepatide might be slightly more effective:
SURMOUNT Clinical Trials (Tirzepatide): These trials demonstrated significant weight loss with tirzepatide, with participants achieving an average weight reduction of 16% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) of their initial body weight over approximately 72 weeks.
STEP Clinical Trials (Semaglutide): The STEP program studies showed that a 2.4 mg dose of semaglutide led to an average weight loss of about 15% over 68 weeks. More recent research exploring a higher 7.2 mg dose of semaglutide has demonstrated even greater weight loss, averaging 20.7% over 72 weeks.
While the study durations and dosages differ, the available evidence indicates that tirzepatide, particularly at higher doses, may lead to greater average weight loss compared to the standard 2.4 mg dose of semaglutide. However, the 7.2 mg semaglutide data suggests the gap might be narrowing with higher doses of semaglutide.
A meta-analysis comparing the two drugs indicated that tirzepatide led to a larger percentage of total body weight loss when compared to semaglutide. Furthermore, a separate study specifically looking at people with overweight or obesity also concluded that tirzepatide was more effective for weight loss.
Side Effect Profiles
Because both tirzepatide and semaglutide affect how quickly the stomach empties, they can cause similar potential side effects, mainly involving the digestive system. Common side effects include:
-
Nausea
-
Vomiting
-
Diarrhea
-
Constipation
-
Abdominal pain
Research suggests that although the frequency of side effects might be comparable between the two drugs, the intensity and the exact nature of these effects could differ. Some findings suggest that people taking tirzepatide might have slightly less severe gastrointestinal issues compared to those on semaglutide, but individual experiences can vary.
Dosage and Administration
Both medications are administered as once-weekly subcutaneous injections. However, their titration schedules and maximum maintenance doses differ:
Semaglutide (Wegovy): It usually begins with a small dose of 0.25mg, which is then slowly raised over several months until reaching a standard maintenance dose of 2.4mg. A larger dose of 7.2mg is currently being studied.
Tirzepatide (Zepbound): Also starts at a low dose (2.5mg) and is gradually increased to a maximum maintenance dose of 15mg.
The higher maximum dose of tirzepatide contributes to its potentially greater weight loss efficacy.
Choosing the Right Medication
The “best” medication ultimately depends on individual factors, including:
Weight loss goals: Individuals seeking more significant weight loss might find tirzepatide a more potent option based on current data.
Tolerance to side effects: Personal tolerability to the gastrointestinal side effects might influence the choice.
Underlying health conditions: While both medications are approved for treating type 2 diabetes, they may have different effects on other health issues, such as cardiovascular risk.
Clinical trials have demonstrated that semaglutide offers cardiovascular benefits, but similar data for tirzepatide is still being gathered. Notably, tirzepatide has also received approval for treating moderate to severe obstructive sleep apnea in adults who are obese.
Cost and insurance coverage: The cost and insurance coverage for these medications can vary significantly. Some analyses suggest tirzepatide might offer better cost value for weight reduction.
Conclusion
Both tirzepatide and semaglutide are very good at helping people lose weight. Based on the information we have now, tirzepatide might be a bit more effective on average because it works in two ways and can be given at a higher dose.
However, both medications have similar potential side effects, and the best option for you should be decided after talking to a healthcare professional who can consider your specific health, how much weight you want to lose, and other important things.
Key Takeaways
Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide is a GLP-1 receptor agonist.
Studies have shown that tirzepatide might result in more significant average weight loss compared to typical doses of semaglutide. However, research into higher doses of semaglutide is also showing encouraging outcomes.
Side effect profiles are similar, mainly involving gastrointestinal issues.
Dosage and titration schedules differ between the two medications.
Ultimately, the most suitable option depends on your unique circumstances and should be decided in consultation with your doctor.